Peptide blend (cognitive)

Semax + Selank

Semax + Selank is a vial blend of two peptides; the app lists a half-life of about 3 minutes (0.05 h) carried over from the component entries, and no study of the blend itself was identified.

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Semax + Selank after one dose: 50% at ~0.05 h, 25% at 0.1 h, 12.5% at 0.15 h.

Drawn from the half-life in the app's model, ~0.05 h. The model's figures

Semax + Selank is a pre-mixed blend of two peptides, entered in the app as Semax 5 mg and Selank 5 mg (10 mg total per vial), with vendor ratios that vary. The app lists its routes as nasal and SubQ. Both components are heptapeptides: Semax is Met-Glu-His-Phe-Pro-Gly-Pro and Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro.1 Dolotov and colleagues (Institute of Molecular Genetics, Russian Academy of Sciences, Brain Research, 2006) write that Semax "is an analog of the adrenocorticotropin fragment (4-10)".2 Filatova and colleagues (Frontiers in Pharmacology, 2017) describe Selank as "a synthetic analog of the natural immunopeptide taftsin" that "was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences".3

The app grades the evidence for the blend as emerging, and its entry states that no study has tested the two peptides together. No study of the two peptides given together as a blend was identified in PubMed (14 records for "semax selank") or ClinicalTrials.gov (0 studies for "semax"). The human studies below test Semax alone or Selank alone, in different populations, and are reported mostly in Russian journals. For most of them only the PubMed record text was available, so details that sit in the full papers (adverse event tables, funding statements, the authors' limitation sections) are reported here only where that text gives them.

The laboratory findings below concern each component separately; none was run on the blend. In rats, Dolotov and colleagues reported that a single application of Semax at 50 microg/kg body weight gave a maximal 1.4-fold increase of hippocampal BDNF protein, a 1.6-fold increase of trkB tyrosine phosphorylation and 3-fold and 2-fold increases of exon III BDNF and trkB mRNA.2 Kost and colleagues (Bioorganicheskaia khimiia, 2001) reported a dose-dependent effect of both peptides on enkephalin-degrading enzymes of human serum, with an IC50 of 10 microM for Semax and 20 microM for Selank.1 They wrote that "it can be assumed that one of the mechanisms of biological activity of Semax and Selank is related to this inhibitory activity of theirs".1 Zozulya and colleagues (Bulletin of Experimental Biology and Medicine, 2001) reported that Selank "dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin (IC50 15 microM)", a figure that differs from the 20 microM in the Kost paper.4,1 In patients, Zozulia and colleagues (2008) reported that those with generalized anxiety disorder and neurasthenia "had the decreased level of tau(1/2) leu-enkephalin", and that an increase in this parameter was observed during treatment with Selank "mostly in patients with GAD".5 In a human neuroblastoma cell line (IMR-32), Filatova and colleagues reported: "We found no changes in the mRNA levels of the genes studied under the effect of Selank", for 84 genes of the GABAergic system; this is a cell result, not a result in people.3 In the same cell study, Selank combined with GABA led to nearly complete suppression of the expression changes seen with GABA alone, and Selank combined with olanzapine altered more genes than olanzapine alone; the paper states support from a Russian Science Foundation grant.3 In rats with 6-hydroxydopamine-induced parkinsonism, Slominsky and colleagues (2017) reported that "both peptides did not affect motor activity of rats in elevated cross shaped maze" and that "Selank decreased level of anxiety of rats with toxic damage of DA neurons".6

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.05 h
Bioavailability
95%
Typical dose
400–1200 mcg/day
Route
nasal, SubQ
Time to peak
~0.05 h

The second column of the table holds the app's own figures, shown beside what the retrieved sources report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~0.05 h (about 3 minutes)The app's entry says both peptides have a plasma half-life of about 3 minutes, carried over from the component entries; none of the retrieved records gives a half-life in people for either peptide, and in rats intranasal Semax is reported to undergo "rapid enzymatic degradation"7
Bioavailability95%The app's entry says the 95% figure is carried over from the component entries and that nasal bioavailability of both peptides in humans is not well characterised; none of the retrieved records gives a bioavailability figure
Time to peak~0.05 hIn rats, 0.093% of the introduced radioactivity per gram was in the brain 2 minutes after intranasal tritium-labelled Semax (50 microg/kg); that is a measurement time, not a reported time to peak7
Duration8 hThe app's entry describes the downstream effects as proposed and lasting hours; in 60 patients, Medvedev and colleagues report that "The anxiolytic effect lasted for a week after last receiving the peptide" (Selank, after a treatment course)9
ModelOne-compartmentThe app's entry states that the kinetics are modelled from the component entries and not measured for the mix

Shevchenko and colleagues (Bioorganicheskaia khimiia, 2006) gave tritium-labelled Semax intranasally to rats and reported that of the radioactivity found in the brain at 2 minutes, "80% of this radioactivity belonged to Semax, and the rest, to its metabolites", with the tripeptide Pro-Gly-Pro prevailing in biological samples.7 Zolotarev and colleagues (2006) studied Selank in blood plasma and reported "the pentapeptide TKPRP, tripeptide TKP, and dipeptides RP and GP were shown to be the major products of Selank biodegradation".8 Filatova and colleagues state that the tripeptide Pro-Gly-Pro at the end of the Selank molecule "provides metabolic stability and duration of action of the drug".3 These are measurements in rats and in laboratory preparations; none gives a human plasma half-life, so there is no figure from the sources to place beside the app's 0.05 h.

4

Human studies

No human study of the blend was identified. The table lists studies of Semax alone or Selank alone, each in a different population, and every detail comes from the PubMed record of the paper.

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Zozulia and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 2008 (Selank)5Comparative study listed as a randomised controlled trial; Selank against medazepam; funding and blinding not stated in the record562 patients with generalized anxiety disorder and neurasthenia (30 on Selank, 32 on medazepam)5Not stated in the record5"The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects"5
Medvedev and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 2014 (Selank)9Comparative clinical trial of Selank against phenazepam; group sizes not stated in the record960 patients with phobic-anxiety and somatoform disorders9Not stated in the record9"Pronounced anxiolytic and mild nootropic effects of selank were demonstrated"; "The anxiolytic effect lasted for a week after last receiving the peptide"9
Medvedev and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 2015 (Selank with phenazepam)10Randomised controlled trial; phenazepam alone against Selank plus phenazepam1030 on phenazepam alone and 40 on Selank plus phenazepam, with anxiety-phobic, hypochondriac and somatoform disorders10Not stated in the record10"The combined treatment decreased the level of undesirable side-effects of phenazepam"10
Gusev and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 1997 (Semax)11Controlled clinical trial of Semax added to combined intensive therapy against conventional therapy1130 patients on Semax and 80 controls in the acute period of hemispheric ischemic stroke11Most effective daily doses reported: 12 mg (moderate strokes) and 18 mg (severe strokes); courses of 5 and 10 days11Semax "had some influence on the rate of restoration of the damaged neurological functions"11
Gusev and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 2018 (Semax)12Clinical trial; Semax-treated and untreated subgroups within early and late rehabilitation groups12110 patients after ischemic stroke126000 mcg/day, 2 courses of 10 days with a 20-day interval12Plasma BDNF higher with Semax; "Administration of semax and high BDNF levels accelerated the improvement and ameliorated the final outcome of Barthel score index"12
Serdiuk and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova 2007 (Semax)13Open-label trial in sequential groups of patients, no comparator described in the record1327 patients with motor neuron disease13Intranasal 1% solution, 12 mg daily, two 10-day courses with a 2-week break13No effect on the course of chronic partial denervation or on clinical estimates; quality-of-life total "significantly improves", maximal on day 1013
Polunin and colleagues, Vestn Oftalmol 2000 (Semax)14Controlled clinical trial; nasal drops, endonasal electrophoresis or control14Patients with optic nerve disease; number not stated in the record14Not stated in the record14Semax added to the therapeutic complex "had a favorable impact on the intensity and rate of recovery and improved the visual functions"14
Panikratova and colleagues, Dokl Biol Sci 2020 (Semax or Selank)15Resting-state fMRI before and 5 and 20 minutes after injection of Semax, Selank or placebo1552 healthy participants15Not stated in the record15Differences in functional connectivity between the right amygdala and a region of the right temporal cortex between groups and conditions15

Deeper analysis: Zozulia and colleagues, Selank against medazepam (2008)

Zozulia and colleagues reported the trial in the Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova in 2008; the PubMed record lists it as a Randomized Controlled Trial.5 The record states that "Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied", with Selank in 30 and medazepam in 32.5 Patient state was assessed with the Hamilton, Zung and CGI psychometric scales, and enkephalin activity in blood serum was measured.5 The authors conclude that "The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects".5 The record gives no scale scores, effect sizes, p-values, doses, treatment length, adverse events or discontinuations, so none are reported here, and a comparison with medazepam is not a comparison with placebo. The record lists no funding statement, competing-interest statement or limitations statement. One listed author, Miasoedov NF, appears with an Institute of Molecular Genetics, Russian Academy of Sciences affiliation in a 2015 record by Medvedev and colleagues, and Filatova and colleagues state that Selank "was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences".10,3

Deeper analysis: Medvedev and colleagues, Selank against phenazepam (2014) and with phenazepam (2015)

Medvedev and colleagues compared Selank with phenazepam in 60 patients with phobic-anxiety and somatoform disorders (ICD-10 codes F40.2-9, F41.1-9 and F45.0-1), in the Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova in 2014.9 The record reports "Pronounced anxiolytic and mild nootropic effects of selank were demonstrated", that the anxiolytic effect "lasted for a week after last receiving the peptide", and that "Selank had a positive impact on the quality of life of the patients".9 Tolerability is named as an objective, but the record gives no adverse event rates, group sizes, doses, scale scores or p-values, carries the labels Clinical Trial and Comparative Study rather than Randomized Controlled Trial, and lists no funding or limitations statement.9 The 2015 trial by Medvedev and colleagues compared phenazepam alone (30 patients) with Selank plus phenazepam (40 patients), with tolerability rated on the UKU scale.10 Its authors report that "The positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS" and that "The combined treatment decreased the level of undesirable side-effects of phenazepam".10 That result is for Selank added to phenazepam, not Selank alone, and the record gives no numbers, funding or limitations statement.10 Myasoedov NF, an author of the 2015 record, is listed there with an Institute of Molecular Genetics, Russian Academy of Sciences affiliation, and Filatova and colleagues state that Selank "was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences"; the 2014 record lists Miasoedov NF as an author without an affiliation.10,3,9

Deeper analysis: Gusev and colleagues, Semax after ischemic stroke (2018)

Gusev and colleagues examined 110 patients after ischemic stroke to evaluate "the efficacy of semax and timing of rehabilitation on the dynamics of plasma BDNF levels, motor performance, and Barthel index score".12 Patients were divided into early (89±9 days) and late (214±22 days) rehabilitation groups, each subdivided into Semax-treated and untreated subgroups; the regimen was 2 courses of 6000 mcg/day for 10 days with a 20-day interval.12 The record reports that "Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels which remained high during the whole study period".12 It also reports "a positive correlation between BDNF plasma levels and Barthel score", and the authors conclude that "Early rehabilitation and administration of semax increase BDNF plasma level, speed functional recovery, and improve motor performance".12 The record is labelled a Clinical Trial and does not say whether assignment to Semax was randomised or blinded, gives no effect sizes, p-values, adverse events or discontinuations, and states no limitations or funding; the BDNF and Barthel findings are correlations, and the trial population is people after stroke.12

Deeper analysis: Serdiuk and colleagues, Semax in motor neuron disease (2007)

Serdiuk and colleagues gave Semax (1% solution) intranasally to 27 patients with definite, probable or possible motor neuron disease, 12 mg daily in two 10-day courses with a 2-week break.13 The record describes "The open-label clinical trial of Semax (1% solution) was conducted in sequential groups of patients", although PubMed also lists the publication types Comparative Study and Randomized Controlled Trial.13 The null result is stated plainly: "Semax (1% solution) does not influence either the course of CPD or the dynamics of clinical estimates".13 The record reports that Semax "significantly improves the total estimate of life quality due to the improvement of emotional state and motivation", with the maximal effect on day 10.13 The record gives no adverse events, discontinuations, funding statement or limitations statement; it does note that chronic partial denervation followed a forward-backward course, which "did not allow to recommend the follow-up needle EMG with short-term interval for evaluation of drug efficacy monitoring".13 The author list includes Miasoedov NF.13

5

Doses reported in studies and on labels

No label for Semax or Selank was identified: searches of DailyMed for "semax" and for "selank" each returned 0 labels, so the table holds the app's figures and doses from study records.

Table 5.1Doses reported in studies and on labels8 rows
SourceCompound, route and comparatorDoseLength and people
App's entrySemax + Selank blend, nasal or SubQ; no comparator400–1200 mcg/day of blend, equal to 200 to 600 mcg of each peptide at a 1:1 ratio; vial of 5 mg Semax + 5 mg SelankPer day; no study of the blend
Gusev 199711Semax added to combined intensive therapy, against conventional therapy; route not stated in the record12 mg daily (moderate stroke) or 18 mg daily (severe stroke)Courses of 5 and 10 days; 30 on Semax, 80 controls
Gusev 201812Semax, Semax-treated against untreated subgroups; route not stated in the record6000 mcg/day2 courses of 10 days, 20-day interval; 110 patients in all
Serdiuk 200713Semax 1% solution, intranasal; open-label, no comparator described12 mg dailyTwo 10-day courses, 2-week break; 27 patients
Polunin 200014Semax as nasal drops or endonasal electrophoresis, against controlNot stated in the recordNot stated in the record
Zozulia 2008, Medvedev 2014 and 2015 (Selank)5,9,10Selank against medazepam, against phenazepam, and with phenazepamNot stated in the records62, 60 and 70 patients
Dolotov 2006, rats2Semax, single application; animal study50 microg/kg body weightSingle application, rat hippocampus
Shevchenko 2006, rats7Tritium-labelled Semax, intranasal; animal study50 microg/kg in 20 microl of solutionRats of 200-250 g

The Semax doses in the stroke and motor neuron disease trials (6 mg to 18 mg a day) are larger than the 200 to 600 mcg of Semax a day that the app's blend range corresponds to at a 1:1 ratio; those trials tested Semax alone, in patients with disease.11,12,13

None of the PubMed records read for Semax or Selank gives adverse event counts, serious adverse events or discontinuations for either peptide alone, and none concerns the blend. Zozulya and colleagues describe Selank as a peptide "which attenuates behavioral anxiety reactions and does not cause side effects typical of most anxiolytics"; this is the authors' statement in a paper on enkephalin-degrading enzymes, with no event rates given.4 In the 2015 trial the side effects named are those of phenazepam, which the authors report were reduced by the combined treatment: "attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference and orthostatism".10 Vanhee and colleagues (Sciensano, Belgium, Drug Testing and Analysis, 2020) write that controlling laboratories "need to anticipate the uprising of these types of potentially dangerous molecules", a general statement that gives no event data for Semax or Selank.18

The app lists no markers to monitor for the blend. The studies above measured the following, which are findings of those studies and not monitoring advice. Gusev and colleagues measured plasma BDNF in patients after stroke, with Semax "increased BDNF plasma levels which remained high during the whole study period".12 Zozulia and colleagues measured enkephalin activity in blood serum and its tau(1/2) in patients with generalized anxiety disorder and neurasthenia, and Zozulya and colleagues reported a "considerable shortening of enkephalin half-life and reduced total enkephalinase activity in the blood during generalized anxiety".5,4 Uchakina and colleagues reported that in vitro Selank at 10-7 M "completely suppressed gene expression by peripheral blood IL-6 of patients with depression but not of the healthy controls", that IL-6 concentration in the cell culture of peripheral blood of patients rose significantly in the presence of Selank, and that changes of the Th1/Th2 cytokine balance were seen in the serum of patients with generalized anxiety disorder and neurasthenia "who received Selank during 14 days".16

8

Regulatory and anti-doping status

The WADA 2026 Prohibited List text retrieved does not name Semax or Selank.17 Its class S0, "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", covers any pharmacological substance not addressed by other sections of the List "with no current approval by any governmental regulatory health authority for human therapeutic use", and names BPC-157 among examples.17 Whether S0 applies to either peptide therefore depends on their approval status, which the sources retrieved do not settle.17 Polunin and colleagues call Semax a "new Russian drug", while Vanhee and colleagues write that Selank and Semax, "to our knowledge, have not completed any clinical trials".14,18 Vanhee and colleagues (Sciensano, Brussels) report that at the end of 2017 and 2018 two unknown suspicious preparations were encountered that "contained the assumedly cognitive enhancing research peptides Selank and Semax", and that an online search showed such peptides "freely available either as lyophilized powder for injection purposes or are present in nasal sprays".18

9

What is not known

  • Whether the two peptides have been studied together as a blend: searches of PubMed and ClinicalTrials.gov identified no such study, and the app's entry says none exists.
  • The half-life, bioavailability and time to peak of either peptide in people: the app's figures are carried over from component entries, and the retrieved records give rat and laboratory data only.
  • How the app's blend range relates to trial doses: the retrieved Semax trial records that state a dose give 6 to 18 mg a day, and the Selank trial records and the Polunin 2000 record state no dose.
  • Adverse event rates for either peptide alone or for the blend, which none of the records read gives.
  • Whether the human findings have been repeated by groups without N F Miasoedov (Myasoedov in later records) as an author: he is listed on seven of the nine human study records retrieved (Zozulia 2008, Medvedev 2014 and 2015, Gusev 1997, Serdiuk 2007, Panikratova 2020 and Uchakina 2008), and the Gusev 2018 and Polunin 2000 records do not list him.
What is the half-life of Semax + Selank?

The app lists about 3 minutes (0.05 h), carried over from the component entries rather than measured for the blend. None of the records retrieved gives a half-life in people for either peptide; in rats, intranasal Semax is reported to undergo "rapid enzymatic degradation".7

Has Semax + Selank been studied in a clinical trial?

No trial of the blend was identified in PubMed or ClinicalTrials.gov. Human trials of each peptide alone were identified, for example Selank against medazepam in 62 patients and Semax in 110 patients after ischemic stroke.5,12

Is Semax + Selank banned by WADA?

The WADA 2026 Prohibited List text does not name Semax or Selank.17 Class S0 prohibits at all times any pharmacological substance with "no current approval by any governmental regulatory health authority for human therapeutic use", so its application depends on approval status.17

What is Semax?

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro.1 Dolotov and colleagues describe it as "an analog of the adrenocorticotropin fragment (4-10)".2

What is Selank?

Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro.1 Filatova and colleagues describe it as "a synthetic analog of the natural immunopeptide taftsin".3

What did Selank show against medazepam in people with anxiety?

In 62 patients with generalized anxiety disorder and neurasthenia, "The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects".5 The PubMed record gives no doses, scores or adverse events for the trial.5

Does Semax change BDNF in people?

In 110 patients after ischemic stroke, Gusev and colleagues report that Semax "increased BDNF plasma levels which remained high during the whole study period".12 The record does not say whether assignment to Semax was randomised, and it reports a positive correlation between BDNF plasma levels and Barthel score.12 The rat finding is separate: a single application of 50 microg/kg Semax gave a maximal 1.4-fold increase of hippocampal BDNF protein.2

What is the bioavailability of Semax + Selank?

The app lists 95%, carried over from the component entries. The app's entry states that nasal bioavailability of both peptides in humans is not well characterised, and none of the retrieved records gives a figure.

Have Semax and Selank been found in seized products?

Vanhee and colleagues (Sciensano, Belgium, 2020) report two suspicious preparations, encountered at the end of 2017 and 2018, that "contained the assumedly cognitive enhancing research peptides Selank and Semax".18

12

References

  1. Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim 2001;27(3):180-3. PMID 11443939
  2. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006;1117(1):54-60. PMID 16996037
  3. Filatova E, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol 2017;8:89. PMC5328971
  4. Zozulya AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med 2001;131(4):315-7. PMID 11550013
  5. Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova 2008;108(4):38-48. PMID 18454096
  6. Slominsky PA, et al. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Dokl Biol Sci 2017;474(1):106-109. PMID 28702721
  7. Shevchenko KV, et al. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorg Khim 2006;32(1):64-70. PMID 16523722
  8. Zolotarev IuA, et al. Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation. Bioorg Khim 2006;32(2):183-91. PMID 16637290
  9. Medvedev VE, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2014;114(7):17-22. PMID 25176261
  10. Medvedev VE, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova 2015;115(6):33-40. PMID 26356395
  11. Gusev EI, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova 1997;97(6):26-34. PMID 11517472
  12. Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118(3 Pt 2):61-68. PMID 29798983
  13. Serdiuk AV, et al. The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Zh Nevrol Psikhiatr Im S S Korsakova 2007;107(4):29-39. PMID 18379501
  14. Polunin GS, et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol 2000;116(1):15-8. PMID 10741256
  15. Panikratova YR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci 2020;490(1):9-11. PMID 32342318
  16. Uchakina ON, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2008;108(5):71-5. PMID 18577961
  17. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  18. Vanhee C, et al. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Test Anal 2020;12(3):371-381. PMID 31667971